CAJ | 학술논문

目的：研究 M2型丙酮酸激酶同工酶（PKM2）在人体早期非小细胞肺癌（NSCLC）、癌旁正常肺组织及肺炎组织中的表达及临床意义。方法收集外科手术切除并经病理确诊的非小细胞肺癌及癌旁正常组织标本以及纤维支气管镜肺活检病理检查确诊为肺炎的肺组织标本各99例，采用免疫组织化学法检测其 PKM2的表达水平，并分析其表达与临床病理的关系。结果PKM2在 NSCLC 组织、癌旁正常肺组织和肺炎组织中的阳性率分别为69．70％、0％和9．09％。鳞状细胞癌明显高于腺癌（P ＜0．01）、腺鳞癌（P ＜0．05）和其他少见病理类型（P ＜0．01）。肿瘤直径＞3 cm 的 PKM2表达率为76．92％，肿瘤直径≤3 cm 的阳性表达率为42．86％，两组比较差异有统计学意义（P ＜0．01）。有淋巴结转移患者的 PKM2表达率为87．18％，无淋巴结转移者为58．33％，两组比较差异有统计学意义（P ＜0．01）。Ⅰ期和Ⅱ期患者的 PKM2阳性表达率分别为58．62％和85．36％，两组比较差异有统计学意义（P ＜0．01）。结论PKM2在早期 NSCLC 中的表达率升高，对临床早期诊断 NSCLC 有一定的价值。
목적：연구 M2형병동산격매동공매（PKM2）재인체조기비소세포폐암（NSCLC）、암방정상폐조직급폐염조직중적표체급림상의의。방법수집외과수술절제병경병리학진적비소세포폐암급암방정상조직표본이급섬유지기관경폐활검병리검사학진위폐염적폐조직표본각99례，채용면역조직화학법검측기 PKM2적표체수평，병분석기표체여림상병리적관계。결과PKM2재 NSCLC 조직、암방정상폐조직화폐염조직중적양성솔분별위69．70％、0％화9．09％。린상세포암명현고우선암（P ＜0．01）、선린암（P ＜0．05）화기타소견병리류형（P ＜0．01）。종류직경＞3 cm 적 PKM2표체솔위76．92％，종류직경≤3 cm 적양성표체솔위42．86％，량조비교차이유통계학의의（P ＜0．01）。유림파결전이환자적 PKM2표체솔위87．18％，무림파결전이자위58．33％，량조비교차이유통계학의의（P ＜0．01）。Ⅰ기화Ⅱ기환자적 PKM2양성표체솔분별위58．62％화85．36％，량조비교차이유통계학의의（P ＜0．01）。결론PKM2재조기 NSCLC 중적표체솔승고，대림상조기진단 NSCLC 유일정적개치。
Objective To explore the expression of M2 isoform of pyruvate kinase(PKM2)in early non-small cell lung cancer(NSCLC),normal lung tissue adjacent to carcinoma and pneumonia and related clinical significance.Methods Immunohistochemistry was used to detect the expression of PKM2 in NSCLC and normal lung tissue adjacent to carcinoma in 99 cases taken by surgical operation and pneu-monia in 99 cases taken by fiberoptic bronchoscopy lung biopsy,and analyzed the relationship between PKM2 and the clinical characteristics.Results The positive rate of PKM2 expression was 69.70%,0%and 9.09% respectively in NSCLC,normal lung tissue adjacent to carcinoma and pneumonia.The positive rate of PKM2 was the biggest in squamous carcinoma group,adenosquamous carcinoma took the second place.The positive rate of PKM2 expression in patients with lymph node metastasis rate was 87.18%,sig-nificantly higher than that of patients without lymph node metastasis(58.33%),the difference was statisti-cally significant(P <0.01).The positive rate of PKM2 expression in patients with tumors greater than 3cm was 76.92%,significantly higher than that of patients with tumors smaller than or equal to 3cm (42.86%),the difference was statistically significant (P <0.01 ).The positive rate of PKM2 was 58.62% and 85.36% respectively in Ⅰ stage and Ⅱ stage patients,the difference was dramatically dif-ferent(P <0.01).Conclusion The expression of PKM2 was significantly high in human early NSCLC, and it was valuable to early diagnosis of NSCLC.